The situation highlights “the difficulty a competitor would have coming into the market with a biosimilar,” says senior biotech analyst ... FDA's approval for scale-up projects.

Analysts came away from a meeting with Viking’s management with an update on the program that included their thinking on how they would scale up ... while the SPDR S&P Biotech ETF has gained ...